Analyst David Risinger of Leerink Partners maintained a Buy rating on AbbVie, retaining the price target of $210.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
David Risinger has given his Buy rating due to a combination of factors including AbbVie’s strong performance and growth prospects. Despite a reduction in the earnings per share estimate for the second quarter of 2025 due to an IPR&D charge, the company’s revised earnings guidance remains robust. Risinger highlights the momentum of key products like Skyrizi and Rinvoq as significant contributors to AbbVie’s positive outlook. Additionally, the company’s financial health is underscored by a manageable net debt to total capital ratio and an estimated long-term earnings growth rate. These elements collectively support the optimistic stance on AbbVie’s stock performance.
Furthermore, the adjustment in earnings estimates aligns closely with the higher end of AbbVie’s updated guidance range, reflecting confidence in the company’s ability to manage expenses effectively. Risinger maintains a positive outlook on AbbVie, reinforced by the company’s strategic positioning and potential for sustained growth in the healthcare sector. This comprehensive analysis underpins the Buy recommendation, suggesting that AbbVie is well-positioned to deliver value to its shareholders.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $240.00 price target.